a day, and Mucosta ophthalmic solution should be applied 4 times a day.

[Summary of Invention]

[Solution to Problem]

[0004]

The present disclosure provides an aqueous suspension agent with excellent redispersibility, the aqueous suspension agent comprising: (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, which is one of the heterocyclideneacetamide derivatives; or a pharmaceutically acceptable salt or solvate thereof.

[0005]

The present disclosure thus provides the following:

(Item 1)

An aqueous suspension agent comprising: (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof; a cellulosic polymer; and a non-ionic surfactant, wherein the concentration of the cellulosic polymer in the aqueous suspension agent is from about 0.00007 w/v% to about 0.007 w/v%, and wherein the cellulosic polymer is at least one selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose.

(Item 2)

The aqueous suspension agent of the preceding item, wherein the concentration of the cellulosic polymer in the aqueous suspension agent is from about 0.0001 w/v% to about 0.005 w/v%.

(Item 3)

The aqueous suspension agent of any one of the preceding items, wherein the concentration of the cellulosic polymer in the aqueous suspension agent is from about 0.0001 w/v% to about 0.005 w/v%.

(Item 4)
The aqueous suspension agent of any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001 w/v% to about 0.5 w/v%.
(Item 5)
The aqueous suspension agent of any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001 w/v% to about 0.1 w/v%.
(Item 6)
The aqueous suspension agent of any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.01 w/v% to about 0.05 w/v%.
(Item 7)
The aqueous suspension agent of any one of the preceding items, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil.
(Item 8)
The aqueous suspension agent of any one of the preceding items, wherein the concentration of the (E)-2-(7-trifluoro-methylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-

Claims

1. An aqueous suspension agent comprising: (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof; a cellulosic polymer; and a nonionic surfactant, wherein the concentration of the cellulosic polymer in the aqueous suspension agent is from about 0.00007 w/v% to about 0.007 w/v%, and wherein the cellulosic polymer is at least one selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose .

2. The aqueous suspension agent of claim 1, wherein the concentration of the cellulosic polymer in the aqueous suspension agent is from about 0.0001 w/v% to about 0.005 w/v%.

3. The aqueous suspension agent of claim 1 or claim 2, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001 w/v% to about 0.5 w/v%.

4. The aqueous suspension agent of any one of claims 1 to 3, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001 w/v% to about 0.1 w/v%.

5. The aqueous suspension agent of any one of claims 1 to 4, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil.

6. The aqueous suspension agent of any one of claims 1 to 5, wherein the concentration of the (E)-2-(7-trifluoro-

methylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydro-naphthalen-1-yl)acetamide or the pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is from about 0.01% w/v to about 5% w/v.

7. The aqueous suspension agent of any one of claims 1 to 6, further comprising a zinc salt or a silver salt.

8. The aqueous suspension agent of claim 7, wherein the concentration of the zinc salt or silver salt in the aqueous suspension is from about 0.0001 w/v% to about 0.05 w/v%.

9. The aqueous suspension agent of claim 7 or claim 8, wherein the zinc salt is zinc chloride or zinc sulfate.

10. The aqueous suspension agent of claim 7 or claim 8, wherein the silver salt is silver nitrate.

11. The aqueous suspension agent of any one of claims 1 to 10, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide.